Browse list of available series in The Biomedical & Life Sciences Collection
Recommend The Biomedical & Life Sciences Collection to your librarian
Request to be kept updated on The Biomedical & Life Sciences Collection
Apply for a free trial of The Biomedical & Life Sciences Collection
View all talks & series with full access

Guest (sample access)

Optional Login with Username


        
> Home  /  Biomedical & Life Sciences  /  Series  /  Cancer Therapy  /  Talk Details
SHARE:   Email via Outlook   Email via Web   Facebook   Twitter   |   more
Close SHARE
Please select one of the methods below to share the following page with your collegues:
UGT1A1 polymorphisms and irinotecan toxicity in colorectal cancer patients
Blogger Google Reader
Delicious Linked In
Digg MySpace
Favorites PDF Online
Gmail

Hello. As a guest, you do not have full access to this talk. Click the PLAY button below to watch the sample extract. Alternatively, you may login or review methods of obtaining more access.

    SPEAKER(S)

Prof. Tae Won Kim - Asan Medical Center, University of Ulsan, Korea

Tae Won Kim is a Medical Oncologist at Asan Medical Center. He completed his MD at Seoul National University and undertook a postdoctoral fellowship at the University of Chicago. His current area of interest is pharmacogenetics, colon cancer and new drug development.

Talk Online Publication: Jan 2009

TOPICS COVERED IN UGT1A1 POLYMORPHISMS AND IRINOTECAN TOXICITY IN COLORECTAL CANCER PATIENTS

Irinotecan activity and safety - Metabolism of Irinotecan - Structure of UGT1A - Role of UGT1A1*28 on irinotecan pharmacogenetics - Role of UGT1A1*6 in Asians - Genotype-based dosing of irinotecan - Other candidates: UGT1A enzyme or transporter

How to cite this talk:
Kim, T.W. (2009), "UGT1A1 polymorphisms and irinotecan toxicity in colorectal cancer patients", in Innocenti , F. and Liu , G. (eds), Cancer Therapy: Latest thinking in efficacy and toxicity, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/bio)

Direct talk access link:
http://hstalks.com/lib.php?t=HST37.1995_1_2&c=252

    DETAILED SLIDE INDEX

1. Introduction
2. Irinotecan (CPT-11, camptosar)
3. Treatment of metastatic CRC
4. Safety of irinotecan (1)
5. Safety of irinotecan (2)
6. Illustration of metabolic pathway of irinotecan
7. Glucuronidation of SN-38 vs. toxicity
8. Schematic illustration of UGT1A
9. Candidate polymorphism: UGT1A1*28, (TA)7
10. UGT1A1*28 genotype-phenotype association (1)
11. UGT1A1*28 genotype-phenotype association (2)
12. Revised irinotecan package insert (Mar 2005)
13. Invader: UGT1A1molecular assay (Aug 2005)
14. Role of UGT1A1*28 in metastatic CRC
15. Unanswered questions
16. UGT1A1*28 frequency in 3 different ethnic groups
17. Another candidate polymorphism: UGT1A1*7
18. Frequency of UGT1A1*6 in Asians
19. UGT1A1*6 genotype-phenotype association
20. Efficacy in UGT1A1*28-genotyped patients
21. Irinotecan dose and hematologic toxicity
22. Individualization of chemotherapy
23. Genotype-based dosing of irinotecan (1)
24. Genotype-based dosing of irinotecan (2)
25. Role of other UGT1A
26. Metabolic pathway of irinotecan: transporters
27. Limitation of previous studies
28. Conclusions
29. END